Description: Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Home Page: www.sol-gel.com
7 Golda Meir Street
Ness Ziona,
7403650
Israel
Phone:
972 8 931 3433
Officers
| Name | Title |
|---|---|
| Dr. Alon Seri-Levy | Co-Founder, CEO & Director |
| Dr. Itzik Yosef | Chief Operating Officer |
| Mr. Gilad Mamlok | Advisor |
| Mr. Moshe Arkin | Executive Chairman of the Board |
| Prof. David Avnir | Co-Founder |
| Mr. Eyal Ben-Or | Chief Financial Officer |
| Ms. Tamar Fishman Jutkowitz | VP & General Counsel |
| Dr. Karine Neimann | VP of Projects & Planning and Chief Chemist |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3569 |
| Price-to-Sales TTM: | 2.0606 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |